The Miami Stem Cell Treatment Center recently announced a series of free public seminars on the use of adult autologous stem cells to address inflammatory and degenerative conditions, which will be offered in February and March. The goal of the seminars is to provide patients with a wide range of diseases accurate information about stem cell therapies — a trend in medicine that is quickly gaining momentum. The seminars will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief and Dr. Nia Smyrniotis, Medical Director and Surgeon.
The Miami Stem Cell Treatment Center (located in Miami, Orlando, Boca Raton and The Villages) and its sister affiliates, the Irvine Stem Cell Treatment Center (located in Irvine, and in Westlake Villages, California) and the Manhattan Regenerative Medicine Medical Group (located in Manhattan, New York), all follow approved investigational protocols that use adult adipose derived stem cells (ADSCs). These ADSCs can be implanted and used to improve the quality of the lives of many patients suffering from chronic, inflammatory and degenerative conditions. The cells are collected from patients’ adipose (fat) tissue, using a mini-liposuction that can be performed in 15 minutes and under local anesthesia.
According to a press release, “SVF is a protein-rich solution containing mononuclear cell lines (predominantly adult autologous mesenchymal stem cells), macrophage cells, endothelial cells, red blood cells, and important Growth Factors that facilitate the stem cell process and promote their activity.”
The Miami Stem Cell Treatment Center does not use embryonic stem cells — only Adult Autologous Stem Cells — and specializes in treating Emphysema, COPD, Asthma, Heart Failure, Heart Attack, Parkinson’s Disease, Stroke, Traumatic Brain Injury, Lou Gehrig’s Disease, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Crohn’s Disease, Muscular Dystrophy, Inflammatory Myopathies, and degenerative orthopedic joint conditions (of the knee, shoulder, hip, and spine).
The free public seminars will take place on Tuesday, February 17, 2015, at the La Hacienda Regional Recreation Center and on March 3rd at the Holiday Inn Express and Suites.
In other developments related to rheumatoid arthritis, in a new study entitled “Dietary supplementation with arachidonic acid increases arachidonic acid content in paw, but does not affect arthritis severity or prostaglandin E2 content in rat adjuvant-induced arthritis model,” authors evaluated in a rat model of arthritis the impact of dietary intake of arachidonic acid on both rheumatoid arthritis severity and lipid content in affected tissues. The authors show that while dietary arachidonic acid intake increased in a dose-dependent manner, no effect was observed in the expression of other lipid mediators or inflammatory cytokines in the rat arthritis model.